The ZDHHC20 antibody is a research tool designed to detect and study the ZDHHC20 protein, a member of the DHHC (Asp-His-His-Cys) family of palmitoyltransferases. These enzymes catalyze protein S-palmitoylation, a post-translational modification critical for regulating protein localization, stability, and interactions. ZDHHC20 contains conserved DHHC catalytic domains and transmembrane regions, enabling its role in lipid modification of target proteins. Research suggests its involvement in diverse cellular processes, including membrane trafficking, signal transduction, and immune responses. Dysregulation of ZDHHC20 has been implicated in diseases such as cancer, where altered palmitoylation may influence tumor progression and metastasis, and neurological disorders linked to synaptic protein dysfunction.
The antibody is typically generated using immunogens derived from specific ZDHHC20 epitopes (e.g., N-terminal or catalytic domains) and validated via techniques like Western blotting, immunofluorescence, and immunohistochemistry. Specificity is often confirmed using knockout cell lines or tissues. Commercial ZDHHC20 antibodies are widely used to explore its expression patterns, substrate interactions, and pathological roles. Recent studies also highlight its potential as a therapeutic target, driving demand for reliable detection tools. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation. Overall, the ZDHHC20 antibody serves as a vital resource for elucidating the biological and clinical significance of protein palmitoylation.